Literature DB >> 34020745

[Recurrent thrombocytopenia with hemolytic anemia in a boy aged 3 years].

Min-Hui Zeng1, Xiang-Ling He1, Xin Tian1, Yu-Hui Huang.   

Abstract

A boy, aged 3 years and 8 months, had recurrent thrombocytopenia with hemolytic anemia for more than 3 years. The physical examination showed no enlargement of the liver, spleen, and lymph nodes or finger deformities. Laboratory results showed a negative result of the direct antiglobulin test, normal coagulation function, and increases in bilirubin, lactate dehydrogenase and reticulocytes. The results of von Willebrand factor-cleaving protease ADAMTS13 activity assay showed extreme deficiency, and antibody assay showed negative ADAMTS13 inhibitory autoantibodies. Next-generation sequence showed compound heterozygous mutation in the ADAMTS13 gene. The boy was diagnosed with congenital thrombotic thrombocytopenic purpura. This disease may be easily misdiagnosed as Evans syndrome and is difficult to diagnose in clinical practice. The child had developed the disease since birth, but it took 3 years to make a confirmed diagnosis. Therefore, congenital thrombotic thrombocytopenic purpura should be considered for children with jaundice at birth, recurrent thrombocytopenia with hemolytic anemia, and negative results of the direct antiglobulin test. The detection of ADAMTS13 activity and ADAMTS13 inhibitory autoantibodies should be performed as soon as possible for a definite diagnosis, and gene detection should be performed to make a confirmed diagnosis when necessary.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34020745      PMCID: PMC8140340     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  25 in total

1.  Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Marie Scully; Spero R Cataland; Flora Peyvandi; Paul Coppo; Paul Knöbl; Johanna A Kremer Hovinga; Ara Metjian; Javier de la Rubia; Katerina Pavenski; Filip Callewaert; Debjit Biswas; Hilde De Winter; Robert K Zeldin
Journal:  N Engl J Med       Date:  2019-01-09       Impact factor: 91.245

Review 2.  Pediatric thrombotic thrombocytopenic purpura.

Authors:  Bérangère S Joly; Paul Coppo; Agnès Veyradier
Journal:  Eur J Haematol       Date:  2018-08-22       Impact factor: 2.997

Review 3.  Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Authors:  M Saha; J K McDaniel; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-07-27       Impact factor: 5.824

Review 4.  Understanding thrombotic microangiopathies in children.

Authors:  Bérangère S Joly; X Long Zheng; Agnès Veyradier
Journal:  Intensive Care Med       Date:  2018-01-24       Impact factor: 17.440

Review 5.  Diagnosis and management of catastrophic antiphospholipid syndrome.

Authors:  Or Carmi; Maya Berla; Yehuda Shoenfeld; Yair Levy
Journal:  Expert Rev Hematol       Date:  2017-03-13       Impact factor: 2.929

6.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

7.  Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.

Authors:  Bérangère S Joly; Alain Stepanian; Thierry Leblanc; David Hajage; Hervé Chambost; Jérôme Harambat; Fanny Fouyssac; Vincent Guigonis; Guy Leverger; Tim Ulinski; Thérésa Kwon; Chantal Loirat; Paul Coppo; Agnès Veyradier
Journal:  Lancet Haematol       Date:  2016-10-03       Impact factor: 18.959

8.  Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.

Authors:  Eric Mariotte; Elie Azoulay; Lionel Galicier; Eric Rondeau; Fouzia Zouiti; Pierre Boisseau; Pascale Poullin; Emmanuel de Maistre; François Provôt; Yahsou Delmas; Pierre Perez; Ygal Benhamou; Alain Stepanian; Paul Coppo; Agnès Veyradier
Journal:  Lancet Haematol       Date:  2016-04-16       Impact factor: 18.959

9.  Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen).

Authors:  Erin Rooney Riggs; Erica F Andersen; Athena M Cherry; Sibel Kantarci; Hutton Kearney; Ankita Patel; Gordana Raca; Deborah I Ritter; Sarah T South; Erik C Thorland; Daniel Pineda-Alvarez; Swaroop Aradhya; Christa Lese Martin
Journal:  Genet Med       Date:  2019-11-06       Impact factor: 8.822

Review 10.  Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine.

Authors:  Paul Coppo; Adam Cuker; James N George
Journal:  Res Pract Thromb Haemost       Date:  2018-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.